DE2801355C2 - Komplexverbindung aus Ascorbinsäure, dreiwertigem Titan und zweiwertigem Kupfer - Google Patents
Komplexverbindung aus Ascorbinsäure, dreiwertigem Titan und zweiwertigem KupferInfo
- Publication number
- DE2801355C2 DE2801355C2 DE2801355A DE2801355A DE2801355C2 DE 2801355 C2 DE2801355 C2 DE 2801355C2 DE 2801355 A DE2801355 A DE 2801355A DE 2801355 A DE2801355 A DE 2801355A DE 2801355 C2 DE2801355 C2 DE 2801355C2
- Authority
- DE
- Germany
- Prior art keywords
- ascorbic acid
- compound
- divalent copper
- trivalent titanium
- complex compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 title claims description 23
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims description 18
- 229960005070 ascorbic acid Drugs 0.000 title claims description 9
- 235000010323 ascorbic acid Nutrition 0.000 title claims description 9
- 239000011668 ascorbic acid Substances 0.000 title claims description 9
- 239000010936 titanium Substances 0.000 title claims description 8
- 239000010949 copper Substances 0.000 title claims description 7
- 229910052719 titanium Inorganic materials 0.000 title claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 title claims description 5
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 title claims description 5
- 229910052802 copper Inorganic materials 0.000 title claims description 5
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003609 titanium compounds Chemical class 0.000 claims 1
- 238000004820 blood count Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229910000108 silver(I,III) oxide Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/62—Three oxygen atoms, e.g. ascorbic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/003—Compounds containing elements of Groups 4 or 14 of the Periodic Table without C-Metal linkages
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1816/77A GB1549524A (en) | 1977-01-17 | 1977-01-17 | Composition for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2801355A1 DE2801355A1 (de) | 1978-07-20 |
| DE2801355C2 true DE2801355C2 (de) | 1986-11-06 |
Family
ID=9728526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2801355A Expired DE2801355C2 (de) | 1977-01-17 | 1978-01-13 | Komplexverbindung aus Ascorbinsäure, dreiwertigem Titan und zweiwertigem Kupfer |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS6045638B2 (US08197722-20120612-C00042.png) |
| DE (1) | DE2801355C2 (US08197722-20120612-C00042.png) |
| FR (1) | FR2377393A1 (US08197722-20120612-C00042.png) |
| GB (1) | GB1549524A (US08197722-20120612-C00042.png) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0046409A1 (en) * | 1980-08-20 | 1982-02-24 | Erwin Günther Walliczek | A process for the preparation of a solution of a cuprous complex; solutions of the cuprous complexes for use in the therapeutic treatment of the human or animal body; and a method of therapeutic treatment of a plant |
| IL63928A (en) * | 1980-10-04 | 1985-02-28 | Byk Gulden Lomberg Chem Fab | Pharmaceutical compositions comprising beta-diketone metal complexes,some such novel complexes and their preparation |
| HU183536B (en) * | 1981-08-04 | 1984-05-28 | Nitrokemia Ipartelepek | Process for preparing feed additive or feed promoting the weight increase of domestic animals |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR805335A (fr) * | 1935-10-10 | 1936-11-17 | Préparation et isolement des composés de l'acide ascorbique et de ses produits d'oxydation avec les métaux susceptibles de donner des sels complexes | |
| FR807877A (fr) * | 1935-10-10 | 1937-01-23 | Préparation et isolement de sels complexes de l'acide ascorbique et de ses produits d'oxydation |
-
1977
- 1977-01-17 GB GB1816/77A patent/GB1549524A/en not_active Expired
-
1978
- 1978-01-13 DE DE2801355A patent/DE2801355C2/de not_active Expired
- 1978-01-17 FR FR7801246A patent/FR2377393A1/fr active Granted
- 1978-01-17 JP JP53002839A patent/JPS6045638B2/ja not_active Expired
Non-Patent Citations (1)
| Title |
|---|
| NICHTS-ERMITTELT |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2377393B1 (US08197722-20120612-C00042.png) | 1981-07-31 |
| JPS6045638B2 (ja) | 1985-10-11 |
| JPS53111056A (en) | 1978-09-28 |
| DE2801355A1 (de) | 1978-07-20 |
| FR2377393A1 (fr) | 1978-08-11 |
| GB1549524A (en) | 1979-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2240782A1 (de) | Verfahren zur herstellung eines eisensaccharid-komplexes | |
| DE60107272T2 (de) | Eisenverbindungen | |
| DE2945790A1 (de) | Neutrales kristallines salz einer basischen l-aminosaeure mit l-apfelsaeure und verfahren zu dessen herstellung | |
| DE2604481C2 (US08197722-20120612-C00042.png) | ||
| DE3000743C2 (de) | Arzneipräparat auf der Basis eines Salzes der Acetylsalicylsäure und einer basischen Aminosäure | |
| DE2801355C2 (de) | Komplexverbindung aus Ascorbinsäure, dreiwertigem Titan und zweiwertigem Kupfer | |
| DE2060601B2 (de) | Nahrungsergänzungsmittel | |
| EP0000704A1 (de) | Polyäther, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Lipidabsorptionshemmer | |
| EP2047855B1 (de) | Antitumorale, antibakterielle und antivirale pharmazeutische zusammensetzung (varianten) | |
| EP0100974A1 (de) | Teilchenförmiges Futterzusatzmittel für Wiederkäuer | |
| DE3619426A1 (de) | Mittel zur erhoehung der widerstandskraft gegen erkaeltungskrankheiten bei patienten mit eingeschraenkter lungenfunktion | |
| EP1001756B1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE2715384C3 (de) | Arzneimittel gegen Diarrhöen | |
| EP2886131A1 (de) | Transparentes Gel | |
| EP0207193A2 (de) | Synergistische Kombination von Flupirtin und 4-Acetamido-phenol | |
| DE1617306C3 (de) | Zahnputzmittel zur Verhinderung von Zahnerkrankungen | |
| DE1936723C2 (de) | Salze von Chinarindenalkoloiden und Verfahren zu ihrer Herstellung | |
| EP0334177B1 (de) | Oral verabreichbares pharmazeutisches Mittel, insbesondere zur Eisen- und Magnesiumsubstitutionstherapie | |
| DE2728589A1 (de) | Verwendung von 2-(2,2-disubstituierten)-aethylimidazolinen bei der bekaempfung von diabetes | |
| EP0820771A2 (de) | Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und eine Magnesiumverbindung enthält | |
| DE2716535B2 (de) | Verwendung von D-Glucaro-13-lactam | |
| EP0667154A1 (de) | Verwendung von Flavolignanen als Adjuvans in der Tumortherapie. | |
| CH634546A5 (de) | Verfahren zur herstellung von komplexen verbindungen von aminodicarbonsaeuren mit magnesium und halogenen. | |
| DE1944906A1 (de) | Aliphatische Sulfate des Erythromycins | |
| DE2314387C3 (de) | Arzneimittel zur Behandlung bösartiger Neubildungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |